There is no routine screening for ovarian cancer.
Major randomized controlled trials, such as the UKCTOCS, have demonstrated that population screening does not significantly reduce ovarian cancer mortality, and as a result, routine screening is not recommended for the general public.
The claim states that there is no routine screening for ovarian cancer. High-quality clinical evidence and major trials (like UKCTOCS) and recent consensus reviews explicitly confirm that population-wide routine screening is not recommended or implemented because it fails to reduce mortality and lacks sufficient test performance. Thus, the claim is supported.
Usha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, Andy Ryan, Jatinderpal K Kalsi, Naveena Singh, Anne Dawnay, Lesley Fallowfield, Alistair J McGuire, Stuart Campbell, Steven J Skates, Mahesh Parmar, Ian J Jacobs. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. 2025. https://doi.org/10.3310/ckuy6010
The large UKCTOCS randomized controlled trial established that population screening for ovarian cancer does not significantly reduce disease-specific deaths, leading to the conclusion that general population screening cannot be recommended.
See more details
Salomon C, Razo-Azamar M, Gentry-Maharaj A, Rice GE, Menon U. Advances in ovarian cancer screening and early detection: from biomarkers to multivariate index assays.. 2026. https://doi.org/10.1080/14737159.2025.2608820
Recent clinical literature affirms that existing modalities lack sufficient sensitivity and specificity, and no ovarian cancer screening test is currently approved for routine use.
The paper trail · every fact has a biography
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work · Dispute this receipt